NEWARK, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 2013 Regen Med Investor Day to be held on Wednesday, April 17, 2013, at the Harmonie Club, 4 East 60th Street, New York, NY. Mr. McGlynn is scheduled to make his presentation at 4:00 pm EDT. In addition, Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc., will participate in an expert panel discussion on "Therapeutics for a Broad Range of CNS Diseases," which is scheduled to begin at 11:05 am EDT. All the day's events, including Mr. McGlynn's presentation and Dr. Huhn's panel discussion, will be webcast live and available at http://alliancerm.org/rmdaywebcast.
The 2013 Regen Med Investor Day, which is organized by the Alliance for Regenerative Medicine (ARM) and co-hosted by leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, is intended to provide institutional, strategic and venture investors unique insight into the investment thesis for regenerative medicine-based therapeutics and tools. The 2013 Regen Med Investor Day will begin with keynote talks by Jeff Jonas, President of Shire Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life Sciences. These will be followed by focused discussions among key opinion leaders, top investment analysts and senior company executives on three of the industry's more prominent target indications, including disorders of the central nervous system (CNS). Company presentations, showcasing 16 leading, publicly traded small- and mid-cap companies in the field, will be in the afternoon.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. More information is available at http://alliancerm.org/event/regen-med-investor-day.
A replay of the webcast will be available on ARM's website shortly after the event.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive data for the first patient cohort. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of the Company's HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and in its subsequent reports on Forms 10-Q and 8-K.